Connect with us

Industry News

Pressure BioSciences Announces Two More Purchase Orders for its Revolutionary BaroShear K45 Processing System for Manufacturing Water-Soluble CBD

Avatar

Published

on

default_cannabis_industry_cannamaps

Company Forecasts All 12 Systems in Current Build Cycle Will Be Sold by September 30, 2019 and Reiterates Previous Guidance for More Than Doubling of Annual Revenue in 2020 SOUTH EASTON, MA, Aug. 22, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE – Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” or the “Company”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide life sciences industry, today announced it has received two additional purchase orders for its revolutionary BaroShear™ K45 processing system. This novel processing system is based on the Company’s proprietary Ultra Shear Technology™ (UST™) platform. The BaroShear K45 is a unique and powerful nanoemulsification system designed to resolve one of the most critical problems facing the CBD industry today: the extremely poor solubility of CBD Oil in water.CBD has been broadly demonstrated to offer powerful health benefits, addressing a variety of challenging medical conditions. CBD is a non-psychoactive compound that is extracted from the cannabis plant in an oil form. After ingestion of CBD, because oils are not well absorbed into the water-based bodies of humans and other animals, most of the CBD is flushed from the system, leaving little of the product absorbed and circulating to provide its beneficial properties. Because of these solubility issues, many CBD products on the market today contain a costly and inefficient over-abundance of CBD, and/or undesirable chemicals that may have been added to try and improve the CBD Oil’s solubility in water. Processing most oil-based products into nanometer-size droplets in emulsions with water (“nanoemulsions”) often improves their absorption, medicinal benefits, visual appearance, and sensory presentation. Unfortunately, traditional processing methods used to make nanoemulsions struggle with this challenge. PBI’s patented UST platform uses ultra-high pressure to create extreme shearing forces that create highly stable, homogenized nanoemulsions of materials that normally do not mix, such as CBD Oil and water. To learn more about PBI’s proprietary UST process and to watch UST-processed CBD Oil fully dissolve in water, please use the following link: How a World Leader in Pressure Technology Made CBD Oil Truly Water Soluble. PBI announced its initial production commitment for 12 BaroShear K45 systems, and the sale of its first system in late July. The two new purchase orders announced today (and included in an August 16, 2019 Form 8k filing) were received from NanoPeak Solutions, Inc., a private company located in Vancouver, BC, and from a private company located in Las Vegas, NV.Mr. Bruce Leitch, President of NanoPeak Solutions, Inc., said: “We fully appreciate both the challenges and the significant emerging market opportunity of having the ability to deliver CBD in a form that allows for greater absorption and enhanced bioavailability.  Multiple scientific studies have indicated that CBD should be processed via nanoemulsion technology in order to be truly water soluble and resulting in consumer products possessing both shelf stability and consistent dosages. NanoPeak has spent significant time reviewing and assessing various nanoemulsification platforms and the Company has great confidence that PBI’s BaroShear K45 System will be instrumental in NanoPeak having the ability to offer the highest quality ingredients to be utilized in CBD products of all types.”The total cannabinoids market is expected to hit $89 billion by 2024 (https://mordorintelligence.com/industry-reports/cannabis-market), with CBD Oil-based products being the cornerstone of the non-psychoactive portion of this exploding market. For CBD products commonly consumed orally – including CBD Oils in edibles and beverages – absorption into the body is typically below 10% (ERTH 8/28/2018: Water Soluble CBD – The Science of Nanoemulsions and Bioavailability). PBI believes that processing with the UST-based BaroShear K45 system will deliver greatly improved absorption results (potentially as high as 90%) for CBD and a universe of other oil-based supplements.Richard T. Schumacher, President and CEO of PBI, said: “The number of reports that focus on the poor absorption of CBD in current CBD Oil-based products continues to increase, and the message they are sending is very clear: CBD Oil needs to be processed into a nanoemulsion to make it truly water-soluble, which is necessary to increase the absorption and bioavailability of the CBD Oil within the body. The critical issue of poor water-solubility/bioavailability of current CBD infused products was addressed in a recent World Health Organization critical review report on CBD (http://nnw.fm/m9l2B), which stated: “Probably due to its poor aqueous solubility, the absorption of CBD from the gastrointestinal tract is erratic, and the resulting pharmacokinetic profile is variable. Bioavailability from oral delivery was estimated to be 6% due to significant first-pass metabolism.”Mr. Schumacher continued: “We are very pleased that the NanoPeak Solutions Team has purchased one of the initial BaroShear K45 systems. We are further pleased that NanoPeak and PBI have agreed in principal to a long-term collaboration that both companies believe will be mutually-beneficial; to that end, the companies have agreed that payment for the BaroShear K45 system will be made to PBI in a combination of cash and common stock in NanoPeak Solutions, Inc., thus binding the companies together in a way that will go well beyond the typical customer-vendor relationship. NanoPeak Solutions intends to engage with various research institutions in furthering the shared technology platform knowledge base and undertaking clinical trials along with ongoing new product development and innovation. We look forward to working closely with NanoPeak as they grow into a strong manufacturing partner and manufacturer of CBD infused products.”About Pressure BioSciences, Inc. Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired, patented technology from BaroFold, Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., CBD Oil and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing technologies.Forward Looking StatementsThis press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential” or “continue” or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law. For more information about PBI and this press release, please click on the following website link: http://www.pressurebiosciences.com                                                               Please visit us on Facebook, LinkedIn, and Twitter. Investor Contacts
Richard T. Schumacher, President and CEO, PBI
(508) 230-1828 (T)
Bruce Leitch, President, NanoPeak Solutions, Inc.
(604) 605-8522 (T)

Original story can be found at: http://www.globenewswire.com/news-release/2019/08/22/1905468/0/en/Pressure-BioSciences-Announces-Two-More-Purchase-Orders-for-its-Revolutionary-BaroShear-K45-Processing-System-for-Manufacturing-Water-Soluble-CBD.html?f=22&fvtc=5&fvtv=41223728

Continue Reading

Industry News

500 Patients in 100 Days and Investing in Australian Companies: Compass Lifestyle Clinics Looks towards the future of Medicinal Cannabis

Avatar

Published

on

default_cannabis_industry_cannamaps

SYDNEY, Australia, Aug. 27, 2019 (GLOBE NEWSWIRE) — Today, Starbuds International (“the Company”), parent company to Compass Lifestyle clinics (“Compass”), is pleased to provide an update on its activities since launching its first medical clinic in Sydney Australia in May.
500 patients in 100 daysWithin 100 days of opening, Compass Lifestyle Clinics has seen over 500 patients and helped provide safe access to medicinal cannabis under the watch of the Therapeutic Goods Association (“TGA”). The company is now looking to expand its capacity to serve patients across Australia.Dr. Teresa Towpik wins Doctor of the YearAt the 2019 Cannabis Industry Awards for Australia, the honours of Doctor of the Year were taken home by Compass Chief Medical Officer, Dr. Teresa Towpik. The award comes as further validation for the work Dr. Towpik has done to bring cannabis into the mainstream as a medicinal cannabis advocate in addition to her tireless work both educating doctors around prescribing as well as serving patients.Investment in Australian Cannabis Grower Medigrowth AustraliaThe Company has also secured a minority investment in Australian Medicinal cannabis late stage applicant and cultivation company Medigrowth Australia. The investment further strengthens Compass’ position in the supply chain, combining patient-centric advocacy & GP education with a leading Australian medicinal cannabis grower and extractor.
             
“Our strategic partnership with Compass consolidates our commitment to patient access and advocacy. We look forward to working with the highly respected team at Compass to educate, inspire and innovate.” says Adam Guskich, Co founder of Medigrowth Australia. “Our combined resources will prove instrumental in providing access to pure, safe, trusted and affordable Australian grown pharma grade medicinal cannabis for Australian patients.”
Along with this announcement, Brianna Martyn, Co-Founder of Starbuds International, has been appointed to the Strategic Advisory Board“Australia has welcomed us with open arms”, says Dave Martyn, President of Compass. “When we did our research, we could see Australians were underserved when it came to safe access to medicinal cannabis. At the same time, from an economic standpoint, we’ve seen what an incredible job creator the cannabis sector has been in Canada. We’ve been fortunate to partner with some of the top cannabis leaders in Australia to play a part in ensuring safe patient access while also helping to grow the industry at large.”The news at a time when medical cannabis acceptance is rapidly growing. With monthly approvals increasing recent news around the removal of red tape surrounding cannabis companies, Compass is poised to expand it’s presence in Australia as it looks towards multi-clinic expansion as well as further investment opportunities.   Those interested in learning more about Compass Lifestyle Clinics can do so at https://compassclinics.com.au or in Canada at https://compasscannabis.ca.About Compass Cannabis ClinicsCompass Cannabis Clinic is a medical cannabis service provider whose core business is focused on providing educational and consultative services to those looking for access to medicinal cannabis. Compass works with a number of Licenced Producers to ensure the right product for the patient while eliminating product bias for prescribers. With several clinics operating in Canada and over 13,000 patients served, Compass has now expanded into Australia with its first clinic in Sydney. Compass Lifestyle Clinics, located in Sydney, with plans for rapid expansion. Compass also operates recreationally in Canada as Starbuds Canada.For further information contactDaniel Winer
Marketing Director
daniel.winer@compassclinics.com.au 
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION
This news release contains certain forward-looking statements and forward-looking information (collectively referred to herein as “forward-looking statements”) within the meaning of applicable Canadian securities laws. All statements other than statements of present or historical fact are forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “anticipate”, “achieve”, “could”, “believe”, “plan”, “intend”, “objective”, “continuous”, “ongoing”, “estimate”, “outlook”, “expect”, “may”, “will”, “project”, “should” or similar words, including negatives thereof, suggesting future outcomes. Management of the Company believes the expectations reflected in such forward-looking statements are reasonable as of the date hereof but no assurance can be given that these expectations will prove to be correct and such forward-looking statements should not be unduly relied upon. Various material factors and assumptions are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking statements. Those material factors and assumptions are based on information currently available to the Company, including data from publicly available governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of the retail cannabis industry which the Company believes to be reasonable. However, although generally indicative of relative market positions, market shares and performance characteristics, such data is inherently imprecise. While the Company is not aware of any misstatement regarding any industry or government data presented herein, the retail cannabis industry involves risks and uncertainties and is subject to change based on various factors.
Forward-looking statements are not a guarantee of future performance and are subject to and involve a number of known and unknown risks and uncertainties, many of which are beyond the control of the Company, which may cause the Company’s actual performance and results to differ materially from any projections of future performance or results expressed or implied by such forward-looking statements.Any forward-looking statements are made as of the date hereof and, except as required by law, the Company assumes no obligation to publicly update or revise such statements to reflect new information, subsequent or otherwise.A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/e52045f5-e820-43b1-9d91-9f5d3e5e9622

Original story can be found at: http://www.globenewswire.com/news-release/2019/08/27/1907468/0/en/500-Patients-in-100-Days-and-Investing-in-Australian-Companies-Compass-Lifestyle-Clinics-Looks-towards-the-future-of-Medicinal-Cannabis.html?f=22&fvtc=5&fvtv=41223728

Continue Reading

Industry News

Radient Technologies Inc. Releases First Quarter 2020 Financial Results and Provides Corporate Update

Avatar

Published

on

default_cannabis_industry_cannamaps

EDMONTON, Alberta, Aug. 27, 2019 (GLOBE NEWSWIRE) — Radient Technologies Inc. (“Radient” or the “Company”) (TSX Venture: RTI; OTCQX: RDDTF), a global innovator in the industrial scale extraction and downstream processing of premium grade cannabis and hemp derivatives, has released its financial results for the first quarter of its fiscal year 2020, ending June 30, 2019. The financial statements and Management’s Discussion & Analysis are available under the Company’s profile at www.SEDAR.com.
Financial Highlights:Strong cash position:As at June 30th, 2019 the Company had maintained a cash position of CAD $23.5 million.Large inventory for increased future revenue generation:As part of the Company’s business model, which will allow it to benefit from advantages related to cost, scale, and yield provided by its proprietary extraction and processing platform, Radient has secured a large inventory of cannabis biomass (valued at CAD $21.7 million), which will be processed at its Edmonton I manufacturing facility into extracts for sale to Canadian Licensed Producers. This inventory is mainly the result of Radient’s purchase of CAD $19.5 million worth of dried cannabis biomass from Canadian Licensed Producers, including Aurora Cannabis Inc. (“Aurora”), which the Company initially announced on July 8, 2019.
 
Radient has secured buyers for the majority of these extracts. Revenues earned from the sale of these extracts are expected to be in excess of the value of the current total inventory of dried cannabis biomass (CAD $21.7 million), and the Company expects this will have a meaningful positive impact on its earnings reported across fiscal Q2 2020 and/or fiscal Q3 2020. Due to various supply chain factors including shipment of biomass, product analysis and delivery of final product, the Company expects the majority of this revenue will be reported in fiscal Q3 2020.
Corporate Update:Successful scale up of throughput at Edmonton I facility:Since the commencement of extraction and processing activities at its Edmonton I facility (“Edmonton I”) in March 2019, Radient has begun to significantly scale up throughput batch sizes of cannabis biomass by multiples of 5x – 10x, in line with the Company’s expectations. Edmonton I has a throughput capacity of 56,0000 kg/ year of cannabis at full capacity.Recovery and quality of cannabinoids has exceeded expectations:Radient is pleased to report results from the scale-up at Edmonton I have proven:Cannabinoid recovery (yield) from biomass is consistently above 90%, and up to 99%.Cannabis extracts have maintained product stability, including negligible cannabinoid degradation.  Hemp processing line on track for completion:Radient’s Edmonton II Facility (“Edmonton II”), dedicated to the extraction and downstream processing of CBD from hemp, is on track for completion at the end of calendar 2019. Upon completion, Edmonton II is expected to have an annual throughput capacity of 420,000 kg/ year of hemp.Expansion into Germany:Radient’s Germany facility (‘Germany”) is expected to begin initial commissioning in the second half of calendar 2020, scaling up to its full capacity of 280,000 kg of cannabis and 2.8 million kg/ year of hemp thereafter. Please refer to the subsection titled “Germany” under “Cannabis Activities” in the MD&A for further details.Expanded throughput capacity in Canada:Radient’s Edmonton III facility (“Edmonton III”), currently under construction, is expected to be commissioned in the second half of calendar 2020, scaling up to its full capacity of 280,000 kg of cannabis and 2.8 million kg/ year of hemp thereafter.
 
Upon completion of its Edmonton II, Edmonton III and Germany facilities, Radient will have a combined total annual throughput capacity of more than 600,000 kg/year of cannabis and more than 6 million kg/ year of hemp across Canada and Germany.EU GMP compliance:Radient is building both its Edmonton III and Germany facilities to be EU GMP compliant.Post-Reporting:Improved working capital via Amended Loan Facility Agreement:The Company announced the amendment of its original loan facility with Moskowitz Capital Mortgage Fund on August 26, 2019, which increased the amount of the loan from CAD $5.5 million to $8.5 million, and extended the maturity date of the loan from November 1, 2020 to November 1, 2021.Consumer product manufacturing:In anticipation of upcoming changes to the Cannabis Act, which will make the production and sale of edible cannabis, cannabis extracts and cannabis topicals legal in Canada as of October 2019, Radient has been developing a range of compounds and formulations to meet anticipated demand of its clients. In particular, Radient has been focusing on formulation development for various vaping products, edible cannabis products, cannabis extracts and cannabis topicals that its clients will be introducing into the Canadian marketplace. The Company has developed vaping liquid formulations for commercialization and is preparing its manufacturing operations for the production of vaping liquids and cartridge filling, and expects the production of vaping liquid will begin in fiscal Q3 2020. Management Commentary:“This is a key inflection point for Radient,” Denis Taschuk, President & CEO of Radient commented. “During fiscal Q1 2020 we proved our processing and manufacturing capabilities with respect to cannabis, and subsequently acquired a large inventory of cannabis biomass in order to develop white label cannabinoid derivatives for sale to Canadian LPs. We see this as a significant turning point for Radient as a revenue generating company, and we expect this will be clearly reflected in our Q2 2020 and/ or Q3 2020 financials.”  About Radient 
Radient Technologies provides industrial-scale manufacturing solutions for premium natural ingredients and products. Utilizing its patented MAP™ extraction technology, Radient delivers superior customer outcomes in terms of ingredient purity, yield, and cost, serving global market leaders in industries such as foods & beverages, nutraceuticals, pharmaceuticals, cosmetics, and personal care. Since 2016, Radient has expanded its offerings to enter the cannabinoids market, using its proprietary platform to provide premium ingredients including those that contain a broad range of cannabinoid and terpene profiles. Please visit www.radientinc.com for more information.
SOURCE: Radient Technologies Inc.Investors please contact: William (Bill) Wasson, Senior VP of Capital Markets and Investor Relations: wwasson@radientinc.comMedia/press please contact: Caitlin Cheadle, Director of Communications: ccheadle@radientinc.comForward Looking Information:
This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. Forward-looking information includes, without limitation, statements regarding the growth of the Company’s business operations; the construction of the Company’s facilities; the Company’s future revenues and timing of such revenues; the Company’s future products; the Company’s ability to sell its products and attract new customers; the expected throughput capacities at its facilities as set out in the “Corporate Update” section above;  the future recovery and quality of the Company’s extracts; the Company’s ability to expand its business internationally; the Company’s ability to grow its business in the cannabis sector and the Company’s future plans. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved”. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Radient, as the case may be, to be materially different from those expressed or implied by such forward-looking information. Although Radient has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. Radient does not undertake to update any forward-looking information, except in accordance with applicable securities laws.
NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Original story can be found at: http://www.globenewswire.com/news-release/2019/08/27/1907438/0/en/Radient-Technologies-Inc-Releases-First-Quarter-2020-Financial-Results-and-Provides-Corporate-Update.html?f=22&fvtc=5&fvtv=41223728

Continue Reading

Industry News

Cannabis World Congress & Business Exposition Brings Industry’s Top Conference Program to Los Angeles

Avatar

Published

on

default_cannabis_industry_cannamaps

NEW YORK, Aug. 27, 2019 (GLOBE NEWSWIRE) — via CannabisNewsWire – Leading Edge Expositions, a company specializing in B2B trade show production, is proud to announce further details of the upcoming Cannabis World Congress & Business Exposition (CWCBExpo) in Los Angeles, California. It will run from September 26 – 28, 2019, at the Los Angeles Convention Center.
The expo has garnered a number of high-powered sponsors. Their diamond sponsor, Freed, is a prominent CBD company known for promoting healthy living. Other big sponsors include Marcum LLP, an accounting group; Zuber Lawler, a global law firm; and CCELL, known for its disruptive vaping technology. These and other leading companies in the cannabis space have come together to help make CWCBExpo a highly valuable and memorable occasion.Event organizers have also ensured the conference schedule will be packed with interesting and informative speeches, workshops and networking opportunities for all guests in attendance. The keynote address, scheduled for September 26, will be given by Steve White, CEO of Harvest, Inc. He will discuss social justice in the cannabis industry.Other speeches on the agenda will cover the cannabis industry from a myriad of angles, including the medical field, business, law and growers. For those interested in business and law, there will be additional workshops detailing how to manage the blossoming cannabis industry and what laws and regulations business owners should be aware of while their businesses grow.Finally, to provide greater ROI to every guest, speaker and sponsor attending, the expo will include multiple networking events designed to foster new business relationships to capitalize on the fast-growing market. On the evenings of September 26 and 27, CWCBExpo will offer networking opportunities for guests to unwind while making useful connections. Attendees are also encouraged to get involved in the various workshops to make important connections.Demand for CWCBExpo is sure to grow even further as the event draws closer. Attendees who purchase their tickets now will benefit from discounted pricing. To register for the upcoming Cannabis World Congress & Business Expo in Los Angeles, visit: https://www.cwcbexpo.com/attend-registration-los-angeles/About Cannabis World Congress & Business Expositions (CWCBExpo)
CWCBExpos are the premier business-to-business events for the legalized cannabis industry and are held 3 times per year in the largest financial, business, and media markets—New York, Los Angeles and Boston. Connect on Twitter, Facebook, Instagram, and LinkedIn: @cwcbexpo.
General Inquiries:
Leading Edge Expositions, LLC
Paramus, New Jersey
201.580.2050 Office
Media Contact:
CannabisNewsWire (CNW) 
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
editor@CannabisNewsWire.com

Original story can be found at: http://www.globenewswire.com/news-release/2019/08/27/1907192/0/en/Cannabis-World-Congress-Business-Exposition-Brings-Industry-s-Top-Conference-Program-to-Los-Angeles.html?f=22&fvtc=5&fvtv=41223728

Continue Reading

Trending